Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02341261
Other study ID # HM20015791
Secondary ID R01DK064814
Status Recruiting
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date April 2022

Study information

Verified date May 2020
Source Virginia Commonwealth University
Contact Brittney Holmberg
Phone 804-552-0014
Email Brittney.holmberg@vcuhealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study will randomize participants with diabetic peripheral neuropathy into two groups. One group of participants will receive standard-of-care counseling while the other group will undergo supervised exercise and counseling to increase physical activity.


Description:

Type 2 diabetes (T2D) affects over 8% of Americans, and half will develop peripheral neuropathy, a progressive injury to the very longest nerves of the body. Our previous research has found that neuropathy can be detected early in its course and followed by examining nerves that reach to the skin using a small punch biopsy. These cutaneous nerves can be injured by high blood glucose, obesity and high triglycerides, but have the potential to regrow in response to treatments that improve these metabolic conditions. The proposed study will randomize participants with mild to moderate diabetic peripheral neuropathy to receive either generic annual counseling or an integrated program of moderate supervised exercise and actigraphy based anti sedentariness counseling.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date April 2022
Est. primary completion date April 2022
Accepts healthy volunteers No
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria:

1. T2D defined by ADA criteria.

2. Peripheral neuropathy based on the Toronto Diabetic Neuropathy Expert Group consensus criteria for "Confirmed diabetic sensorimotor peripheral neuropathy".

3. Moderate DPN severity with a UENS of 2-18.

4. Age between 30 and 75.

5. Under the care of an identified Primary Care Physician (PCP).

Exclusion Criteria:

1. Any alternative cause for peripheral neuropathy. The following tests must have been found normal within the last 12 months or will be performed pre-randomization: vitamin B12, serum protein electrophoresis and immunofixation. ANA and TSH may be obtained if clinically indicated and not available from clinical records.

2. Family history of a non-diabetic neuropathy in a first-degree relative.

3. Severe or longstanding neuropathy: UENS > 18 or history of foot ulceration or amputation.

4. Participants taking Coumadin or oral factor X or thrombin inhibitor therapy will be considered on an individual basis by the site investigator.

5. Severe edema, dermatologic or lower extremity condition that would increase risk of skin biopsy.

6. A serious medical condition that might shorten life span or prevent exercise.

7. Subjects with obesity or hypertension considered in a dangerous range (BMI> 45, systolic BP >170, or diastolic BP >110) and those who fail a medically supervised graded maximal stress test will be excluded from the study for safety reasons.

8. An inability to understand or cooperate with the procedures of the study

9. Females who are pregnant at screening or actively plan to become pregnant during the study period, because of the marked changes in metabolism anticipated during pregnancy.

10. If ,in the investigators assessment, that participation in the study would be limited by a person's weight, size, or other physical condition.

Study Design


Intervention

Behavioral:
Standard Care Counseling

Supervised Exercise and Counseling


Locations

Country Name City State
United States University of Kansas Kansas City Kansas
United States University of Utah School of Medicine Salt Lake City Utah

Sponsors (4)

Lead Sponsor Collaborator
Virginia Commonwealth University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Kansas, University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Intraepidermal Nerve Fiber Density (IENFD) Baseline, 9 months, and 18 months
Primary Change in Quality of Life (NQOL-DN) Questionnaire Results Baseline, 9 months, and 18 months
See also
  Status Clinical Trial Phase
Completed NCT04025320 - The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy N/A
Completed NCT02659007 - Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga Phase 1
Completed NCT01953757 - A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2) N/A
Completed NCT01707979 - NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes N/A
Completed NCT00608439 - Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy Phase 2
Completed NCT00576277 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain Phase 1/Phase 2
Completed NCT00235443 - A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy Phase 2/Phase 3
Completed NCT00830011 - Cognitive Behavioral Therapy for Painful Diabetic Neuropathy N/A
Completed NCT00931879 - Lovaza® and Microvascular Function in Type 2 Diabetes Phase 4
Completed NCT00190970 - The Effect of Ruboxistaurin on Small Fiber Function Phase 2
Completed NCT00101426 - Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Phase 3
Completed NCT00238550 - Study of CBME in the Relief of Painful Diabetic Neuropathy Phase 2
Completed NCT05573685 - Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training N/A
Completed NCT01822925 - Study of DA-9801 to Treat Diabetic Neuropathy Phase 2
Completed NCT01690962 - A Nutritional Intervention for Diabetic Neuropathy N/A
Terminated NCT00993018 - A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy Phase 2
Withdrawn NCT02315235 - The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy N/A
Completed NCT00496457 - Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy Phase 2
Recruiting NCT02606747 - The Balance Control Mechanism of DPN Patients N/A
Completed NCT02068027 - Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy Phase 2